Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14739013 | 0.82 | ELANE (0.36) | ELANECDK5ALDH1A1CHEK1LMNA | |
| SCHEMBL4293410 | 0.81 | ELANE (0.48) | ELANEPDGFRACDK5TYRO3MAPK8 | |
| SCHEMBL3518728 | 0.81 | CHEK1 (0.39) | ELANECDK5MCL1MEN1KMT2A | |
| SCHEMBL9953073 | 0.81 | ELANE (0.40) | ELANEMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL22715315 | 0.81 | PDGFRA (0.57) | ELANEPDGFRACDK5TYRO3MAPK8 | |
| SCHEMBL2732559 | 0.79 | CDK1 (0.43) | ELANEPDGFRACDK5TYRO3MAPK8 | |
| SCHEMBL23783009 | 0.77 | ELANE (0.51) | ELANEPDGFRACDK5TYRO3MAPK8 | |
| SCHEMBL27788207 | 0.77 | ELANE (0.42) | ELANEPDGFRACDK5TYRO3MAPK8 | |
| SCHEMBL27788236 | 0.77 | ELANE (0.48) | ELANEMEN1KMT2AATMPRKD3 | |
| SCHEMBL9952327 | 0.76 | ELANE (0.45) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| CN-101790526-A | 5-heteroaryl substituted indazoles as kinase inhibitors | ABBOTT GMBH & CO KG | 2010-07-28 | — | — | CN | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-1983981-A1 | INDAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LTD. (GB) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007088401-A1 | INDAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | ELANE 4449/4885PDGFRA 701/4885CDK5 114/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | ELANE 4449/4885PDGFRA 701/4885CDK5 114/4885 |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | ELANE 267/4885PDGFRA 1743/4885CDK5 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.